|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Several activators of Nrf2 are known to combat diabetes induced endothelial dysfunction and few are currently in clinical trials.
|
31838079 |
2020 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
More importantly, Nrf2 activation also notably attenuated minute CC-induced endothelial dysfunction.
|
31759967 |
2020 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In summary, our results demonstrate that MLB inhibits NF-κB activation through PKC- and PI3K/Akt-mediated Nrf2 activation in HMEC-1 cells and protects against LPS-induced endothelial dysfunction in murine model of acute inflammation.
|
30617294 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, NRF2 is required for both self-defense and NaB's protection against diabetes-induced aortic endothelial dysfunction.
|
29964168 |
2018 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, tBHQ activates Nrf2 to prevent microvascular endothelial dysfunction, remodeling, and contractility, and moderate ADMA and hypertension at 12-14 days of ANG II infusion, thereby preserving endothelial function and preventing hypertension.
|
29167164 |
2018 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Low nanomolar caffeic acid attenuates high glucose-induced endothelial dysfunction in primary human umbilical-vein endothelial cells by affecting NF-κB and Nrf2 pathways.
|
27412371 |
2017 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A novel role for small molecule glycomimetics in the protection against lipid-induced endothelial dysfunction: Involvement of Akt/eNOS and Nrf2/ARE signaling.
|
27554845 |
2017 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.
|
28253885 |
2017 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, celastrol-induced activation of Nrf2 and inhibition of NADPH oxidase activity were critical for the inhibition of Ang II-mediated endothelial dysfunction, and demonstrated the potential application of celastrol in CVD therapy.
|
28119074 |
2017 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The objective of this study was to assess whether resveratrol could reduce placental oxidative stress and production of anti-angiogenic factors in vitro and/or improve in vitro markers of endothelial dysfunction via Nrf2 activation.
|
29208243 |
2017 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Activators of Nrf2 can be used therapeutically in association with inhibitors of AGE and cross-linking formation to normalize endothelial dysfunction in type 2 diabetes.
|
29085055 |
2017 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
NLGM1 protects against LC-induced human microvascular endothelial dysfunction through increased nitric oxide bioavailability and reduced oxidative and nitrative stress mediated by Nrf-2-dependent antioxidant stress response.
|
27412900 |
2016 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In young smokers with ED a novel further consequence of increased oxidative stress is a repression of Nrf2/ARE pathway leading to GSH depletion.
|
22272327 |
2012 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We hypothesize that diminished Nrf2/ARE activity contributes to increased oxidative stress and mitochondrial dysfunction in the vasculature leading to endothelial dysfunction, insulin resistance, and abnormal angiogenesis observed in diabetes.
|
20524845 |
2011 |